These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29947726)

  • 1. Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.
    Desai RJ; Wyss R; Jin Y; Bohn J; Toh S; Cosgrove A; Kennedy A; Kim J; Kim C; Ouellet-Hellstrom R; Karami S; Major JM; Niman A; Wang SV; Gagne JJ
    Am J Epidemiol; 2018 Nov; 187(11):2439-2448. PubMed ID: 29947726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching on the disease risk score in comparative effectiveness research of new treatments.
    Wyss R; Ellis AR; Brookhart MA; Jonsson Funk M; Girman CJ; Simpson RJ; Stürmer T
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):951-61. PubMed ID: 26112690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring.
    Xu S; Shetterly S; Cook AJ; Raebel MA; Goonesekera S; Shoaibi A; Roy J; Fireman B
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):453-61. PubMed ID: 26875591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.
    Seeger JD; Bykov K; Bartels DB; Huybrechts K; Schneeweiss S
    Drug Saf; 2017 Feb; 40(2):169-181. PubMed ID: 27900668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Calipers for Matching on the Disease Risk Score.
    Connolly JG; Gagne JJ
    Am J Epidemiol; 2016 May; 183(10):937-48. PubMed ID: 27037270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments.
    Patorno E; Glynn RJ; Hernández-Díaz S; Liu J; Schneeweiss S
    Epidemiology; 2014 Mar; 25(2):268-78. PubMed ID: 24487209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
    Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
    Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control.
    Wyss R; Hansen BB; Ellis AR; Gagne JJ; Desai RJ; Glynn RJ; Stürmer T
    Am J Epidemiol; 2017 May; 185(9):842-852. PubMed ID: 28338910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand.
    Nishtala PS; Gnjidic D; Jamieson HA; Hanger HC; Kaluarachchi C; Hilmer SN
    Int J Cardiol; 2016 Jan; 203():746-52. PubMed ID: 26590888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
    Gorst-Rasmussen A; Lip GY; Bjerregaard Larsen T
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1236-1244. PubMed ID: 27229855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials.
    Li G; Holbrook A; Jin Y; Zhang Y; Levine MA; Mbuagbaw L; Witt DM; Crowther M; Connolly S; Chai-Adisaksopha C; Wan Z; Cheng J; Thabane L
    Eur J Epidemiol; 2016 Jun; 31(6):541-61. PubMed ID: 27370013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
    Seeger JD; Bykov K; Bartels DB; Huybrechts K; Zint K; Schneeweiss S
    Thromb Haemost; 2015 Nov; 114(6):1277-89. PubMed ID: 26446507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.